Carrington Laboratories and Mannatech Renew Supply Agreement

IRVING, Texas, Jan 13, 2004 -- Carrington Laboratories, Inc. (Nasdaq: CARN), a leading research-based biopharmaceutical and consumer products company, today announced the renewal of a raw materials supply agreement with Mannatech, Inc. (Nasdaq: MTEX). Under the 12-month renewal agreement, Carrington will continue providing Manapol(R) Powder, its proprietary raw material, for use in Mannatech's nutraceutical products.

'Our raw material Manapol Powder has become a key ingredient in dietary and nutritional supplements. The continuance of our agreement with Mannatech reflects the growing acceptance of Carrington products in the nutraceuticals industry,'said Dr. Carlton E. Turner, president and CEO of Carrington.

Mannatech, Inc. is a wellness solutions provider that develops innovative, high quality, proprietary nutritional supplements, topical products and weight management products. Earlier in the year Carrington announced that the companies had reached an agreement in principal, subject to the review and approval by each company's board of directors. Mannatech is a major user of Carrington's patented product by process, Manapol(R) Powder, a proprietary raw material used in nutraceutical products that carry the Dietary Supplement Health and Education Act of 1994 (DSHEA) claim for immune system enhancement.

About Mannatech

Based in Coppell, Texas, Mannatech, Inc. is a wellness solutions provider that develops innovative, high quality, proprietary nutritional supplements, topical products and weight management products which are sold through a global network marketing system throughout the United States and the international markets of Canada, Australia, the United Kingdom, Japan and New Zealand.

About Carrington Laboratories, Inc.

Carrington Laboratories, Inc., is an ISO-certified, research-based biopharmaceutical and consumer products company currently utilizing naturally occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care as well as to manufacture and market the nutraceutical raw materials Manapol(R) and Hydrapol(TM). Carrington Laboratories also manufactures and markets consumer products sold under its AloeCeuticals(R) brand and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. The company's DelSite subsidiary is developing its proprietary GelSite(TM) technology designed to provide controlled release of peptide and protein-based drugs. More than 120 patents in 26 countries protect Carrington Laboratories' technology. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world. For more information, visit .

Certain statements in this release concerning Carrington Laboratories, Inc. may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to subsequent changes in plans by management, delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products, supply of Manapol(R), changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission, including Form 10-Q filed November 14, 2003.

Carrington, Manapol, AloeCeuticals, Hydrapol, GelSite and Acemannan Hydrogel are trademarks, registered trademarks or service marks of Carrington Laboratories, Inc., in the United States and/or other countries. All other trademarks or service marks contained herein are the properties of their respective owners.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.